Growth hormone-releasing hormone in diabetes

Leonid E. Fridlyand, Natalia A. Tamarina, Andrew V Schally, Louis H. Philipson

Research output: Contribution to journalShort survey

7 Citations (Scopus)

Abstract

Growth hormone-releasing hormone (GHRH) is produced by the hypothalamus and stimulates growth hormone synthesis and release in the anterior pituitary gland. In addition, GHRH is an important regulator of cellular functions in many cells and organs. Expression of GHRH G-Protein Coupled Receptor (GHRHR) has been demonstrated in different peripheral tissues and cell types, including pancreatic islets. Among the peripheral activities, recent studies demonstrate a novel ability of GHRH analogs to increase and preserve insulin secretion by beta-cells in isolated pancreatic islets, which makes them potentially useful for diabetes treatment. This review considers the role of GHRHR in the beta-cell and addresses the unique engineered GHRH agonists and antagonists for treatment of type 2 diabetes mellitus. We discuss the similarity of signaling pathways activated by GHRHR in pituitary somatotrophs and in pancreatic beta-cells and possible ways as to how the GHRHR pathway can interact with glucose and other secretagogues to stimulate insulin secretion. We also consider the hypothesis that novel GHRHR agonists can improve glucose metabolism in Type 2 diabetes by preserving the function and survival of pancreatic beta-cells. Wound healing and cardioprotective action with new GHRH agonists suggest that they may prove useful in ameliorating certain diabetic complications. These findings highlight the future potential therapeutic effectiveness of modulators of GHRHR activity for the development of new therapeutic approaches in diabetes and its complications.

Original languageEnglish (US)
Article number129
JournalFrontiers in Endocrinology
Volume7
Issue numberOCT
DOIs
StatePublished - Oct 10 2016

Fingerprint

Growth Hormone-Releasing Hormone
Insulin-Secreting Cells
Diabetes Complications
Islets of Langerhans
Type 2 Diabetes Mellitus
Somatotrophs
Insulin
Hormone Antagonists
Glucose
Anterior Pituitary Gland
G-Protein-Coupled Receptors
Wound Healing
Growth Hormone
Hypothalamus
Therapeutics

Keywords

  • Diabetic complications
  • GLP-1
  • Insulin
  • Islet
  • Pancreatic beta-cell

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Growth hormone-releasing hormone in diabetes. / Fridlyand, Leonid E.; Tamarina, Natalia A.; Schally, Andrew V; Philipson, Louis H.

In: Frontiers in Endocrinology, Vol. 7, No. OCT, 129, 10.10.2016.

Research output: Contribution to journalShort survey

Fridlyand, Leonid E. ; Tamarina, Natalia A. ; Schally, Andrew V ; Philipson, Louis H. / Growth hormone-releasing hormone in diabetes. In: Frontiers in Endocrinology. 2016 ; Vol. 7, No. OCT.
@article{2d3aaa43ff514ca5883bce9ad96a320b,
title = "Growth hormone-releasing hormone in diabetes",
abstract = "Growth hormone-releasing hormone (GHRH) is produced by the hypothalamus and stimulates growth hormone synthesis and release in the anterior pituitary gland. In addition, GHRH is an important regulator of cellular functions in many cells and organs. Expression of GHRH G-Protein Coupled Receptor (GHRHR) has been demonstrated in different peripheral tissues and cell types, including pancreatic islets. Among the peripheral activities, recent studies demonstrate a novel ability of GHRH analogs to increase and preserve insulin secretion by beta-cells in isolated pancreatic islets, which makes them potentially useful for diabetes treatment. This review considers the role of GHRHR in the beta-cell and addresses the unique engineered GHRH agonists and antagonists for treatment of type 2 diabetes mellitus. We discuss the similarity of signaling pathways activated by GHRHR in pituitary somatotrophs and in pancreatic beta-cells and possible ways as to how the GHRHR pathway can interact with glucose and other secretagogues to stimulate insulin secretion. We also consider the hypothesis that novel GHRHR agonists can improve glucose metabolism in Type 2 diabetes by preserving the function and survival of pancreatic beta-cells. Wound healing and cardioprotective action with new GHRH agonists suggest that they may prove useful in ameliorating certain diabetic complications. These findings highlight the future potential therapeutic effectiveness of modulators of GHRHR activity for the development of new therapeutic approaches in diabetes and its complications.",
keywords = "Diabetic complications, GLP-1, Insulin, Islet, Pancreatic beta-cell",
author = "Fridlyand, {Leonid E.} and Tamarina, {Natalia A.} and Schally, {Andrew V} and Philipson, {Louis H.}",
year = "2016",
month = "10",
day = "10",
doi = "10.3389/fendo.2016.00129",
language = "English (US)",
volume = "7",
journal = "Frontiers in Endocrinology",
issn = "1664-2392",
publisher = "Frontiers Media S. A.",
number = "OCT",

}

TY - JOUR

T1 - Growth hormone-releasing hormone in diabetes

AU - Fridlyand, Leonid E.

AU - Tamarina, Natalia A.

AU - Schally, Andrew V

AU - Philipson, Louis H.

PY - 2016/10/10

Y1 - 2016/10/10

N2 - Growth hormone-releasing hormone (GHRH) is produced by the hypothalamus and stimulates growth hormone synthesis and release in the anterior pituitary gland. In addition, GHRH is an important regulator of cellular functions in many cells and organs. Expression of GHRH G-Protein Coupled Receptor (GHRHR) has been demonstrated in different peripheral tissues and cell types, including pancreatic islets. Among the peripheral activities, recent studies demonstrate a novel ability of GHRH analogs to increase and preserve insulin secretion by beta-cells in isolated pancreatic islets, which makes them potentially useful for diabetes treatment. This review considers the role of GHRHR in the beta-cell and addresses the unique engineered GHRH agonists and antagonists for treatment of type 2 diabetes mellitus. We discuss the similarity of signaling pathways activated by GHRHR in pituitary somatotrophs and in pancreatic beta-cells and possible ways as to how the GHRHR pathway can interact with glucose and other secretagogues to stimulate insulin secretion. We also consider the hypothesis that novel GHRHR agonists can improve glucose metabolism in Type 2 diabetes by preserving the function and survival of pancreatic beta-cells. Wound healing and cardioprotective action with new GHRH agonists suggest that they may prove useful in ameliorating certain diabetic complications. These findings highlight the future potential therapeutic effectiveness of modulators of GHRHR activity for the development of new therapeutic approaches in diabetes and its complications.

AB - Growth hormone-releasing hormone (GHRH) is produced by the hypothalamus and stimulates growth hormone synthesis and release in the anterior pituitary gland. In addition, GHRH is an important regulator of cellular functions in many cells and organs. Expression of GHRH G-Protein Coupled Receptor (GHRHR) has been demonstrated in different peripheral tissues and cell types, including pancreatic islets. Among the peripheral activities, recent studies demonstrate a novel ability of GHRH analogs to increase and preserve insulin secretion by beta-cells in isolated pancreatic islets, which makes them potentially useful for diabetes treatment. This review considers the role of GHRHR in the beta-cell and addresses the unique engineered GHRH agonists and antagonists for treatment of type 2 diabetes mellitus. We discuss the similarity of signaling pathways activated by GHRHR in pituitary somatotrophs and in pancreatic beta-cells and possible ways as to how the GHRHR pathway can interact with glucose and other secretagogues to stimulate insulin secretion. We also consider the hypothesis that novel GHRHR agonists can improve glucose metabolism in Type 2 diabetes by preserving the function and survival of pancreatic beta-cells. Wound healing and cardioprotective action with new GHRH agonists suggest that they may prove useful in ameliorating certain diabetic complications. These findings highlight the future potential therapeutic effectiveness of modulators of GHRHR activity for the development of new therapeutic approaches in diabetes and its complications.

KW - Diabetic complications

KW - GLP-1

KW - Insulin

KW - Islet

KW - Pancreatic beta-cell

UR - http://www.scopus.com/inward/record.url?scp=84995379978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995379978&partnerID=8YFLogxK

U2 - 10.3389/fendo.2016.00129

DO - 10.3389/fendo.2016.00129

M3 - Short survey

VL - 7

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

SN - 1664-2392

IS - OCT

M1 - 129

ER -